Year II · No. 665 · 1,823 entries Tuesday, October 27, 2026 ES EN Get the weekly digest

Thesis Almanac

US · 31 entries · 28 publications

NVO

Novo Nordisk

Entries
31
Bullish
8
Bearish
1
First
Jan 31, 2025
Latest
Oct 15, 2026

▲ 8 bullish ▼ 1 bearish · 22 no stance

More bullish than bearish among those that state a stance.

Jan 25 – Oct 26 · per month

Full performance tracking Pro · free during launch

Alpha of every thesis on NVO at 1, 3 and 6 months and since publication, and the full chart vs its benchmark.

Free during launch: log in or sign up with your email to see it.

Sign up free

Timeline

Newest to oldest
  1. October 2026 4 entries
  2. September 2026 6 entries
  3. August 2026 3 entries
  4. July 2026 1 entry
  5. June 2026 1 entry
  6. April 2026 1 entry
  7. February 2026 2 entries
  8. January 2026 3 entries

    Substack · Torghatten Capital · Arne Ulland

    Investment Thesis - Novo Nordisk ($NVO)

    Disclaimer: Please note that this is not financial advice. What follows are my own thoughts on the investment case, captured on a still, cold Saturday evening this autumn.

    NVO4,372 words

    Since publication −38.8% α −49.3 pp vs S&P 500 · USD

  9. December 2025 1 entry
  10. November 2025 2 entries
  11. October 2025 1 entry

    Substack · The J. Nicholas · Jacob B

    Novo Nordisk Isn't A Quality Company

    Great valuation, exceptional fundamentals, but qualitatively mediocre at best

    NVO2,236 words

    Since publication −28.0% α −43.2 pp vs S&P 500 · USD

  12. September 2025 1 entry

    Substack · Secret Sauce Investing

    Novo Nordisk Write Up 💉

    Shedding pounds for fat profits.

    NVO5,547 words

    Since publication −30.2% α −46.4 pp vs S&P 500 · USD

  13. August 2025 1 entry

    Substack · Flyer Wealth

    Novo Nordisk (NVO): Biggest Buy In The Market?

    After a fall from GLP-1 grace, Novo Nordisk is looking to claw back into relevancy, as shares of the pharmaceutical ADR have dipped nearly 65% in one year.

    NVO656 words

    Since publication −21.5% α −42.0 pp vs S&P 500 · USD

  14. July 2025 1 entry

    Substack · Torghatten Capital · Arne Ulland

    Novo Nordisk: A Tough Lesson

    On May 6th, I wrote a post about Novo Nordisk and how it was, in my view, a victim of its own hype.

    BullishNVO1,111 words

    Since publication −16.9% α −38.0 pp vs S&P 500 · USD

  15. June 2025 2 entries

    Substack · Flyer Wealth

    3 Undervalued Stocks vs. 3 Overvalued Stocks.

    An important part of stock market investing isn’t just whether you own a company or not; it’s what price you own it at.

    BullishNVO358 words

    Since publication −43.3% α −67.0 pp vs S&P 500 · USD

    Substack · Flyer Wealth

    HIMS & NVO Plummet On Unexpected Breakup…

    After Novo Nordisk announced an abrupt collaboration cancellation, shares of Hims & Hers Health Inc.

    HIMSNVO624 words

    Since publication NVO −43.9% α −71.3 pp vs S&P 500 · USD

  16. January 2025 1 entry

    Funds · Seilern Investment Management

    Novo Nordisk: Many strings to their bow

    In the world of healthcare, there are few companies that elicit such strong reactions from investors and the public as Novo Nordisk and its breakthrough weight loss drug, Wegovy (or its equivalent Ozempic for the…

    NVO1,941 words

    Since publication −53.7% α −80.8 pp vs S&P 500 · USD

There are 3 more low-confidence entries, hidden because the ticker could not be checked in the text. See them in the index →

Prices as of the Oct 27, 2026 close. Past performance does not guarantee future results. Price-only, excluding dividends, in local currency. Data may be delayed or inaccurate. Not investment advice. How it is calculated.